| Identification | Back Directory | [Name]
SDZ 220-581 | [CAS]
174575-17-8 | [Synonyms]
SDZ 220-581
(S)-α-Amino-2'-chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoicacid
alpha-Amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid
(S)-ALPHA-AMINO-2'-CHLORO-5-(PHOSPHONOMETHYL)[1,1'-BIPHENYL]-3-PROPANOIC ACID
[1,1'-Biphenyl]-3-propanoic acid, α-amino-2'-chloro-5-(phosphonomethyl)-, (αS)- | [Molecular Formula]
C16H17ClNO5P | [MDL Number]
MFCD00948721 | [MOL File]
174575-17-8.mol | [Molecular Weight]
369.74 |
| Chemical Properties | Back Directory | [Boiling point ]
613.3±65.0 °C(Predicted) | [density ]
1.478 | [storage temp. ]
Store at RT | [solubility ]
DMSO : 8.57 mg/mL (23.18 mM; Need ultrasonic and warming) | [form ]
Powder | [pka]
1.63±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
SDZ 220-581 is a competitive NMDA receptor antagonist. | [Biological Activity]
Competitive NMDA receptor antagonist (pK i = 7.7). Centrally active following oral administration (ED 50 < 3.2 mg/kg for protection against MES-induced seizures). | [in vivo]
SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action[1]. | Animal Model: | Male OF-l mice (18-26 g)[1] | | Dosage: | 3.2 mg/kg, 10 mg/kg, 32 mg/kg | | Administration: | Oral administration; for 24 hours | | Result: | Dose-dependently protected mice against maximal electroshock seizures (MES) upon oral administration.
|
| [IC 50]
NMDA Receptor | [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|